Literature DB >> 4015725

Inspiratory muscle dysfunction and unexplained dyspnea in systemic lupus erythematosus.

S Jacobelli, R Moreno, L Massardo, S Rivero, C Lisboa.   

Abstract

The role of inspiratory muscle dysfunction in lung volume restriction and unexplained dyspnea was studied in 16 consecutive patients with systemic lupus erythematosus. Maximal mouth inspiratory pressure (PIM) and maximal transdiaphragmatic pressure (Pdi max) were measured. Pdi and its components were determined during quiet breathing. No significant association was found between the activity of the disease, several serologic markers, and the inspiratory muscle dysfunction. No specific anti-skeletal muscle antibody was found in these patients. Significant correlations were found between the degree of dyspnea and PIM (r = -0.69, P less than 0.01) and Pdi max (r = -0.75, P less than 0.001); however, dyspnea did not correlate with specific lung compliance. Vital capacity correlated significantly with the degree of dyspnea (r = -0.813, P less than 0.001) and with Pdi max (r = 0.544, P less than 0.05). No correlation was found between vital capacity and specific lung compliance. We conclude that inspiratory muscle dysfunction can be an important mechanism in the pathogenesis of the lung volume restriction and dyspnea in patients with systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015725     DOI: 10.1002/art.1780280709

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Diaphragmatic paresis: pathophysiology, clinical features, and investigation.

Authors:  G J Gibson
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

2.  Respiration and connective tissue diseases.

Authors:  M J Walport
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-14

3.  Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.

Authors:  Alejandro Robles-Perez; Jordi Dorca; Ivan Castellví; Joan Miquel Nolla; Maria Molina-Molina; Javier Narváez
Journal:  Rheumatol Int       Date:  2020-03-10       Impact factor: 2.631

4.  The "shrinking lung syndrome" in SLE, treatment with theophylline.

Authors:  S Van Veen; A J Peeters; P J Sterk; F C Breedveld
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

Review 5.  Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.

Authors:  Helena Borrell; Javier Narváez; Juan José Alegre; Ivan Castellví; Francesca Mitjavila; María Aparicio; Eulàlia Armengol; María Molina-Molina; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.